In line with this, given the fact that identification of a predictive biomarker is challenging, most agents under development are evaluated as a single agent or in combination with anti-PD(L)1 agents, in immune reactive tumors where anti-PD(L)1 agents are given alone in first line, including indications like PDL1+NSCLC or HNSCC tumors. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.